Nuwellis Study: Epoprostenol Safe for Pediatric Aquadex Therapy

Nuwellis, Inc. announced the acceptance of a new single-center retrospective study in Frontiers in Pediatrics. The study demonstrates that epoprostenol can serve as a safe and feasible alternative anticoagulant during Aquadex therapy in critically ill pediatric patients. This research provides important real-world data supporting an alternative anticoagulation strategy for patients who may not be candidates for conventional therapies, further strengthening the clinical evidence for Aquadex therapy in pediatric critical care.